BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that Sandesh Seth, Actinium’s Chairman and Chief Executive Officer will present at the Biotech Showcase™ 2019 being held on January 7-9.

Celebrates 20 years of growth and innovation to provide better care and cost savings to patients and providers

Bain Capital Double Impact, the impact investing business of Bain Capital, today announced the acquisition of HealthDrive, a specialty provider of on-site dentistry, optometry, podiatry, and audiology to residents in long-term care, skilled nursing, and assisted living facilities.

Bruin Biometrics, LLC (“BBI”) has been granted U.S. Food and Drug Administration (FDA) marketing authorization for the SEM Scanner,

Pliant Therapeutics, Inc., a biotechnology company unraveling and targeting the key biological pathways driving fibrosis, today announced that Keith Cummings, M.D., MBA, has joined the company as chief financial officer and Eduard Gorina, M.D., has joined as vice president, clinical development.

Peloton Therapeutics, Inc., a clinical-stage pharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today that it will be presenting at the 37th Annual J.P. Morgan Healthcare Conference.

Axcella Health Inc. (the “Company,” “Axcella,” or “we”), a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the 37th Annual JP Morgan Healthcare Conference, taking place January 7-10, 2019, at the Westin St. Francis Hotel in San Francisco, CA.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2019 objectives, at the 37th Annual J.P. Morgan Healthcare Conference.

Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases

Vizient, Inc. is extremely pleased by the recent ruling made by a federal district court judge that the Department of Health and Human Services (HHS) “exceeded its statutory authority” when the agency reduced Medicare payments to hospitals participating in the 340B Drug Pricing Program by nearly 30 percent.